1. Search Result
Search Result
Results for "

cognitive function

" in MedChemExpress (MCE) Product Catalog:

58

Inhibitors & Agonists

2

Biochemical Assay Reagents

1

Peptides

14

Natural
Products

3

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-D0195

    Biochemical Assay Reagents Neurological Disease Metabolic Disease
    Acesulfame potassium is an artificial sweetener. Acesulfame potassium (long-term) affects cognitive functions, potentially via altering neuro-metabolic functions in mice .
    Acesulfame potassium
  • HY-109590
    Arachidonic acid
    Maximum Cited Publications
    23 Publications Verification

    Immunocytophyt

    Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology
    Arachidonic acid (Immunocytophyt) is a polyunsaturated omega-6 fatty acid and a major constituent of biomembranes. Arachidonic acid also acts as the substrate for various lipid mediators, such as prostaglandins (PGs). Arachidonic acid improves cognitive response and cardiovascular function .
    Arachidonic acid
  • HY-P3247

    Insulin Receptor Neurological Disease Metabolic Disease
    [D-Ala2]-GIP (human) is a GIP receptor agonist. [D-Ala2]-GIP (human) improves glucose tolerance. [D-Ala2]-GIP (human) shows neuroprotective activity in MPTP-induced Parkinson's disease model. [D-Ala2]-GIP (human) also improves cognitive function and hippocampal synaptic plasticity in obese diabetic rats. [D-Ala2]-GIP (human) can be used for research of type 2 diabetes, Parkinson's disease, etc
    [D-Ala2]-GIP (human)
  • HY-W550739

    Biochemical Assay Reagents Neurological Disease
    Acesulfame is an artificial sweetener. Acesulfame affects cognitive functions, potentially via altering neuro-metabolic functions in mice with long-term .
    Acesulfame
  • HY-D0195R

    Biochemical Assay Reagents Neurological Disease Metabolic Disease
    Acesulfame (potassium) (Standard) is the analytical standard of Acesulfame (potassium). This product is intended for research and analytical applications. Acesulfame potassium is an artificial sweetener. Acesulfame potassium (long-term) affects cognitive functions, potentially via altering neuro-metabolic functions in mice .
    Acesulfame potassium (Standard)
  • HY-126658

    Others Neurological Disease
    Lycophlegmine is an alkaloid isolated from the Lycopodiaceae plant family. Lycophlegmine possesses neuroprotective properties and is useful in the study of neurotransmission and cognitive function .
    Lycophlegmine
  • HY-120276

    GR3027

    GABA Receptor Neurological Disease
    Golexanolone is a GABAA receptor modulating steroid antagonist. Golexanolone reduces peripheral inflammation and neuroinflammation and improves cognitive and motor function in hyperammonemic rats .
    Golexanolone
  • HY-124086

    Others Neurological Disease
    BHQ-O-5HT is a light-activated caged 5-HT protected by a BHQ group. When exposed to light at 365 or 740 nm, BHQ-O-5HT releases 5-HT through 1 or 2 photon excitation, respectively. BHQ-O-5HT can be manipulated in space and time to explore the role of 5-HT in regulating mood, appetite, memory, learning, and other cognitive functions .
    BHQ-O-5HT
  • HY-109590A

    Immunocytophyt sodium salt

    Endogenous Metabolite Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Arachidonic acid (Immunocytophyt) sodium salt is a polyunsaturated omega-6 fatty acid and a major constituent of biomembranes. Arachidonic acid sodium salt also acts as the substrate for various lipid mediators, such as prostaglandins (PGs). Arachidonic acid sodium salt improves cognitive response and cardiovascular function .
    Arachidonic acid sodium salt
  • HY-14824A

    ABT 894 benzenesulfonate

    nAChR Neurological Disease
    Sofinicline benzenesulfonate (ABT 894 benzenesulfonate) is a novel nicotinic acetylcholine receptor agonist, specifically acting on the α4β2 subtype of nAChR (IC50=0.1 nM). Sofinicline benzenesulfonate has the potential to improve cognitive function, including attention, memory and working memory. Sofinicline benzenesulfonate can be used in studies of attention deficit, hyperactivity disorder (ADHD) .
    Sofinicline benzenesulfonate
  • HY-117936

    Others Neurological Disease
    Muscarinic agonist 1, AF267, functions by alleviating cognitive impairments.
    Muscarinic agonist 1
  • HY-D0195S

    Isotope-Labeled Compounds Others
    Acesulfame-d4 potassiumis the deuterium labeledAcesulfame (potassium)(HY-D0195) . Acesulfame potassium is an artificial sweetener. Acesulfame potassium (long-term) affects cognitive functions, potentially via altering neuro-metabolic functions in mice .
    Acesulfame-d4 potassium
  • HY-136093A

    IM156; HL156A; HL271 acetate

    Oxidative Phosphorylation AMPK Neurological Disease Cancer
    Lixumistat (IM156; HL156A; HL271) acetate, a chemical derivative of Metformin (HY-B0627), is a potent and orally active AMPK activator that increases AMPK phosphorylation. Lixumistat (acetate) attenuates aging-associated cognitive impairment in animal model . Lixumistat (acetate) is a potent oxidative phosphorylation (OXPHOS) inhibitor which can be used for the research of solid tumors .
    Lixumistat acetate
  • HY-121650

    Others Neurological Disease
    ADTN is a dopamine receptor agonist that has the activity of promoting dopamine neurotransmission. ADTN can be used to increase the release of neurotransmitters, thereby improving dopamine-related physiological functions. ADTN's potential applications include inhibiting mental illness and improving cognitive function .
    ADTN
  • HY-136093

    HL271; IM156 hydrochloride; HL156A hydrochloride

    Oxidative Phosphorylation AMPK Neurological Disease Cancer
    Lixumistat (HL271) hydrochloride (IM156 hydrochloride; HL156A hydrochloride), a chemical derivative of Metformin (HY-B0627), is a potent AMPK activator that increases AMPK phosphorylation. Lixumistat hydrochloride attenuates aging-associated cognitive impairment in animal model . Lixumistat hydrochloride is a potent oxidative phosphorylation (OXPHOS) inhibitor which can be used for the research of solid tumors .
    Lixumistat hydrochloride
  • HY-107111

    Cholinesterase (ChE) Neurological Disease
    GSK1034702 is a M1 mAChR allosteric agonist. GSK1034702 shows procognitive effects in rodents. GSK1034702 modulates hippocampal function to improve memory encoding in nicotine abstinence model of cognitive dysfunction .
    GSK1034702
  • HY-107111A

    Cholinesterase (ChE) Neurological Disease
    GSK1034702 hydrochloride is a M1 mAChR allosteric agonist. GSK1034702 hydrochloride shows procognitive effects in rodents. GSK1034702 hydrochloride modulates hippocampal function to improve memory encoding in nicotine abstinence model of cognitive dysfunction .
    GSK1034702 hydrochloride
  • HY-B0030
    D-Cycloserine
    4 Publications Verification

    iGluR Bacterial Antibiotic Infection Neurological Disease Cancer
    D-Cycloserine is an antibiotic which targets sequential bacterial cell wall peptidoglycan biosynthesis enzymes. D-Cycloserine is a partial NMDA agonist that can improve cognitive functions. D-Cycloserine can be used for multidrug-resistant tuberculosis research .
    D-Cycloserine
  • HY-N0045
    Ginsenoside Rg1
    5+ Cited Publications

    Panaxoside A; Panaxoside Rg1

    Amyloid-β NF-κB Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Ginsenoside Rg1 is one of the major active components of Panax ginseng. Ginsenoside Rg1 ameliorates the impaired cognitive function, displays promising effects by reducing cerebral levels. Ginsenoside Rg1 also reduces NF-κB nuclear translocation.
    Ginsenoside Rg1
  • HY-N7509

    Gallacetophenone-4-methyl ether

    Others Neurological Disease
    2,3-Dihydroxy-4-methoxyacetophenone is a neuroprotective compound from Cynenchum paniculatum. 2,3-Dihydroxy-4-methoxyacetophenone improves cognitive function and may has the potential for the treatment of Alzheimer's disease research .
    2,3-Dihydroxy-4-methoxyacetophenone
  • HY-B0702

    Adrenergic Receptor Cardiovascular Disease Neurological Disease
    Nicergoline, an ergoline derivative ester of bromonicotinic acid, is a potent, selective and orally active antagonist of α1A-adrenoceptor. Nicergoline has vasodilator effects. Nicergoline also has ameliorative effects on cognitive function in mouse models of Alzheimer's disease .
    Nicergoline
  • HY-133712

    Tunodafil

    Phosphodiesterase (PDE) Neurological Disease
    Yonkenafil (Tunodafil), a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease .
    Yonkenafil
  • HY-125095

    Tunodafil hydrochloride

    Phosphodiesterase (PDE) Cardiovascular Disease Neurological Disease
    Yonkenafil (Tunodafil) hydrochloride, a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil (Tunodafil) hydrochloride may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease .
    Yonkenafil hydrochloride
  • HY-18039

    SEN15924

    Cholinesterase (ChE) Neurological Disease
    WAY-361789 (SEN15924) is an orally active agonist for α7 nicotinic acetylcholine receptor (α7 nAChR) with an EC50 of 0.18 μM. WAY-361789 improves the cognitive function, exhibits potential in ameliorating Alzheimer’s Disease and schizophrenia .
    WAY-361789
  • HY-N5130

    Others Neurological Disease
    Effusol, a phenolic constituent from Juncus effuses, exhibits potent scavenging activity for DPPH and ABTS radicals, with IC50 values of 79 μM and 2.73 μM, respectively. Effusol rescues CA1 LTP attenuated by corticosterone, defending the hippocampal function against stress-induced cognitive decline .
    Effusol
  • HY-103111

    mGluR Neurological Disease
    MMPIP hydrochloride is an allosteric metabotropic glutamate receptor 7 (mGluR7) selective antagonist (KB values 24 -30 nM). MMPIP hydrochloride acts as a pharmacological tool for elucidating the roles of mGluR7 on central nervous system functions. MMPIP hydrochloride alleviates pain and normalizes affective and cognitive behavior in neuropathic mice .
    MMPIP hydrochloride
  • HY-107503

    mGluR Neurological Disease
    MMPIP is an allosteric metabotropic glutamate receptor 7 (mGluR7) selective antagonist (KB values 24 -30 nM). MMPIP acts as a pharmacological tool for elucidating the roles of mGluR7 on central nervous system functions. MMPIP alleviates pain and normalizes affective and cognitive behavior in neuropathic mice .
    MMPIP
  • HY-101282

    Amyloid-β Neurological Disease
    Glutaminyl Cyclase Inhibitor 3 (compound 212 ), a designed anti-Alzheimer’s compound, is a potent human Glutaminyl Cyclase (GC) inhibitor, with an IC50 of 4.5 nM. Glutaminyl Cyclase-IN-1 (compound 212) significantly reduced the brain concentrations of pyroform Aβ and total Aβ and restored cognitive functions .
    Glutaminyl Cyclase Inhibitor 3
  • HY-101586A

    Lu 25-109 maleate

    mAChR Neurological Disease
    Alvameline (Lu 25-109) maleate is a partial agonist of M1 and an antagonist of M2/M3. Alvameline maleate competitively antagonizes contractions induced by ammonium chloride (HY-Y1269) and electrical field stimulation in human detrusor muscle, indicating its potential application in regulating bladder function. Additionally, alvameline maleate can improve cognitive function following traumatic brain injury in rats .
    Alvameline maleate
  • HY-103212B

    B-HT 933

    Others Neurological Disease
    Azepexole (B-HT 933) is a selective α2 adrenergic inducer with over 300-fold selectivity for α2 adrenergic receptors over α1 adrenergic receptors. Azepexole can be used to study the biological functions of α2 adrenergic receptors and inhibition of related diseases. Azepexole may also play a role in regulating mood and improving cognitive function .
    Azepexole
  • HY-168031

    Histamine Receptor Calcium Channel Cholinesterase (ChE) Reactive Oxygen Species Amyloid-β Neurological Disease
    AChE/BChE-IN-21 is a histamine H3 receptor antagonist, calcium channel blocker, and acetylcholinesterase inhibitor. AChE/BChE-IN-21 exhibits neuroprotective activity against H2O2 and Aβ1-40, and can restore cognitive function in AD mice .
    AChE/BChE-IN-21
  • HY-17552
    sn-Glycero-3-phosphocholine
    1 Publications Verification

    Choline Alfoscerate; Alpha-GPC; L-α-GPC

    Cholinesterase (ChE) Endogenous Metabolite Neurological Disease
    sn-Glycero-3-phosphocholine (Choline Alfoscerate) is a precursor in the biosynthesis of brain phospholipids and increases the bioavailability of choline in nervous tissue. sn-Glycero-3-phosphocholine (Choline Alfoscerate) has significant effects on cognitive function with a good safety profile and tolerability, and is effective in the treatment of Alzheimer's disease and dementia .
    sn-Glycero-3-phosphocholine
  • HY-U00033

    Others Neurological Disease
    Iomazenil is a benzodiazepine receptor antagonist with partial inverse agonist activity. Iomazenil can assess the binding potential of central benzodiazepine receptors in the cerebral cortex and may reflect neuronal function in viable tissue. Iomazenil use is associated with improved cognitive function in adult patients with ischemic cerebral pathology after indirect revascularization surgery. Iomazenil demonstrated restoration of benzodiazepine receptor binding potential in the affected hemisphere after surgery on brain SPECT imaging .
    Iomazenil
  • HY-N0272
    Eleutheroside E
    1 Publications Verification

    Apoptosis NF-κB Neurological Disease Inflammation/Immunology
    Eleutheroside E is an important component of ginseng that can be taken orally. Eleutheroside E has anti-inflammatory and antioxidant properties, and it helps reduce apoptosis in heart cells caused by hypoxia-reoxygenation (H/R) damage. Eleutheroside E can improve type 2 diabetes, enhance cognitive function, and has neuroprotective effects .
    Eleutheroside E
  • HY-B0030R

    iGluR Bacterial Antibiotic Infection Neurological Disease Cancer
    D-Cycloserine (Standard) is the analytical standard of D-Cycloserine. This product is intended for research and analytical applications. D-Cycloserine is an antibiotic which targets sequential bacterial cell wall peptidoglycan biosynthesis enzymes. D-Cycloserine is a partial NMDA agonist that can improve cognitive functions. D-Cycloserine can be used for multidrug-resistant tuberculosis research .
    D-Cycloserine (Standard)
  • HY-B0702R

    Adrenergic Receptor Cardiovascular Disease Neurological Disease
    Nicergoline (Standard) is the analytical standard of Nicergoline. This product is intended for research and analytical applications. Nicergoline, an ergoline derivative ester of bromonicotinic acid, is a potent, selective and orally active antagonist of α1A-adrenoceptor. Nicergoline has vasodilator effects. Nicergoline also has ameliorative effects on cognitive function in mouse models of Alzheimer's disease .
    Nicergoline (Standard)
  • HY-168028

    mGluR Neurological Disease
    mGluR2 modulator 5 (Compound 11) is an orally active, selective mGluR2 negative allosteric modulator with an IC50 of 8.9 nM. Pharmacokinetic studies in rats show that mGluR2 modulator 5 can effectively cross the blood-brain barrier. It can modulate cognitive and neurological functions in mood disorders and is suitable for research in the field of neurodegenerative diseases .
    mGluR2 modulator 5
  • HY-B0702S

    Isotope-Labeled Compounds Adrenergic Receptor Cardiovascular Disease Neurological Disease
    Nicergoline- 13C,d3 is the 13C- and deuterium labeled Nicergoline. Nicergoline, an ergoline derivative ester of bromonicotinic acid, is a potent, selective and orally active antagonist of α1A-adrenoceptor. Nicergoline has vasodilator effects. Nicergoline also has ameliorative effects on cognitive function in mouse models of Alzheimer's disease[1][2].
    Nicergoline-13C,d3
  • HY-W236261

    ATEE

    Biochemical Assay Reagents Others
    N-Acetyl-L-tyrosine ethyl ester (ATEE) is a compound commonly used as a food flavoring and supplement. It is an ester of tyrosine, an amino acid found in many proteins. N-Acetyl-L-tyrosine ethyl ester is sweet, nutty and caramelized and is commonly used to enhance the flavor of baked goods, dairy products and beverages. Potential health benefits of N-Acetyl-L-tyrosine ethyl ester include its antioxidant properties and ability to improve cognitive function.
    N-Acetyl-L-tyrosine ethyl ester
  • HY-N9785

    Others Neurological Disease
    1-O-trans-p-Coumaroylglycerol is a compound found in certain plants that has neuroprotective activity. 1-O-trans-p-Coumaroylglycerol has shown potential in protecting against neurodegenerative diseases. 1-O-trans-p-Coumaroylglycerol is also believed to act as a natural antioxidant, and its applications may include improving cognitive function and supporting neurological health .
    1-O-trans-p-Coumaroylglycerol
  • HY-120783

    Others Neurological Disease
    Lu AF58801 is a potent, orally available, brain-penetrant positive allosteric modulator of α7 nicotinic acetylcholine receptors with efficacy in a novel object recognition task in mice. Lu AF58801 was shown to selectively enhance the activity of α7 nicotinic acetylcholine receptors. Lu AF58801 was able to improve cognitive function in mice treated with subchronic fluchlorothiazol (PCP) .
    Lu AF58801
  • HY-167824

    Others Neurological Disease
    SSR180711 is a potent and subtype-selective α7 agonist with activity in Alzheimer's disease and schizophrenia research. SSR180711 can be used to study subtypes of intracerebral hemorrhage associated with cerebral small vessel disease. SSR180711 shows potential in electrophysiological and behavioral studies to evaluate its effects on cognitive function. SSR180711 also has potential for studying cerebrovascular lesions and their effects .
    SSR180711
  • HY-13999A1

    Others Neurological Disease
    NSI-189 phosphate is the phosphate salt form of NSI-189 (HY-13999). NSI-189 phosphate stimulates the neurogenesis of neural stem cells. NSI-189 phosphate exhibits neuroprotective effect in Streptozotocin (HY-13753)-induced diabetic mouse model, improves neurological function and cognitive ability after stroke in rat middle cerebral artery occlusion (MCAo) model, and exhibits antidepressant efficacy .
    NSI-189 phosphate
  • HY-16969
    Dihexa
    5 Publications Verification

    PNB-0408; N-hexanoic-Try-Ile-(6)-amino hexanoic amide; Hexanoyl-Tyr-Ile-Ahx-NH2

    c-Met/HGFR Neurological Disease
    Dihexa, an oligopeptide drug, is an orally active and blood-brain barrier-permeable angiotensin IV analog. Dihexa binds to hepatocyte growth factor (HGF) with high affinity (Kd=65 pM) and potentiates its activity at its receptor, c-Met. Dihexa exhibits excellent antidementia activity and improves cognitive function in animal models. Dihexa may have therapeutic potential as a treatment Alzheimer’s disease .
    Dihexa
  • HY-116753

    Amyloid-β Tau Protein Neurological Disease
    (-)Clausenamide is an active alkaloid isolated from the leaves of Clausena lansium (Lour.) Skeels, and improves cognitive function in both normal physiological and pathological conditions. (-)Clausenamide inhibits β-amyloid (Aβ) toxicity, blocking neurofibrillary tangle formation by inhibiting the phosphorylation of tau protein. (-)Clausenamide exerts a significant neuroprotective activity against Aβ25-35. (-)Clausenamide can be used for researching Alzheimer's disease (AD) .
    (-)Clausenamide
  • HY-17552S

    Choline Alfoscerate-d9; Alpha-GPC-d9; L-α-GPC-d9

    Isotope-Labeled Compounds Cholinesterase (ChE) Endogenous Metabolite Neurological Disease
    sn-Glycero-3-phosphocholine-d9 is the deuterium labeled sn-Glycero-3-phosphocholine. sn-Glycero-3-phosphocholine (Choline Alfoscerate) is a precursor in the biosynthesis of brain phospholipids and increases the bioavailability of choline in nervous tissue. sn-Glycero-3-phosphocholine (Choline Alfoscerate) has significant effects on cognitive function with a good safety profile and tolerability, and is effective in the treatment of Alzheimer's disease and dementia[1][2].
    sn-Glycero-3-phosphocholine-d9
  • HY-116673

    Histone Acetyltransferase Neurological Disease
    TTK21 is an activator of the histone acetyltransferases CBP/p300. TTK21 passes the blood–brain barrier, induces no toxicity, and reaches different parts of the brain when conjugated to glucose-based carbon nanosphere (CSP). TTK21 has beneficial implications for the brain functions of neurogenesis and long-term memory .CSP-TTK21 can ameliorate Aβ-impaired long-term potentiation (LTP). CSP-TTK21 may enhance the transcription of genes that promote synaptic health and cognitive function . CSP-TTK21 is orally effective and leads to improvements in motor functions, histone acetylation dynamics in a spinal injury rat model .
    TTK21
  • HY-116580

    Others Neurological Disease
    AZD-3289 is a potent BACE1 inhibitor with potential Alzheimer's disease inhibitory activity. The application of AZD-3289 is intended to slow the pathological progression of Alzheimer's disease by inhibiting the production of β-amyloid protein. The development of AZD-3289 responds to the need to reduce neurodegenerative changes associated with Alzheimer's disease. As a BACE1 inhibitor, AZD-3289 can effectively reduce the accumulation of β-amyloid peptide in the brain, which may improve cognitive function .
    AZD-3289
  • HY-12501A
    ITI-214
    3 Publications Verification

    Phosphodiesterase (PDE) Neurological Disease
    ITI-214 is a potent, CNS-active, orally bioavailable PDE1 inhibitor (Ki of 58 pM) with excellent selectivity against other PDE family members and against a panel of enzymes, receptors, transporters and ion channels. ITI-214 inhibits recombinant full-length human PDE1A, PDE1B and PDE1C with Kis of 33 pM, 380 pM and 35 pM, respectively. ITI-214 shows efficacy in various animal models of motor and cognitive functions .
    ITI-214
  • HY-117467

    Others Neurological Disease
    BMT-108908 is a negative allosteric modulator with selective activity on the NR2B subtype of the NMDA receptor. BMT-108908 has been shown to damage cognition in research, affecting cognitive functions in multiple areas. BMT-108908 failed to show a significant impact on the γ wave power of the EEG in the experiment, but it had a significant inhibitory and enhancement effect on the β wave and δ wave power. The effects of BMT-108908 differ from those of other NMDA receptor channel blockers such as ketamine and lanimol .
    BMT-108908

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: